Suven Life Sciences will be presenting positive pharmacology data of four advanced molecules from their portfolio of investigational neuroscience new chemical entities (NCEs) at Society for Neuroscience (SFN) 2013 from November 9 to 14, 2013 at San Diego, USA.
The data presentations will highlight Suven’s continued commitment to explore new treatment options addressing unmet medical need through novel mechanisms and targets and address a market size of more than $30 billion.
During SFN-2013 Suven lined up several face to face meetings with major pharma and biotech companies to explore integrated collaborative research programmes (CRP) and also Drug Discovery and Development Support Services (DDDSS) in addition to continued discussions with global Pharma majors regarding their clinical candidate SUVN-502.
Neuroscience is the annual meeting of the SFN and more than 30 thousand neuro-scientists from all over the world covering the major pharma, biotech and clinical research institutes will be participating at this conference.
Key pharmacology, ADME and Safety data on selected NCEs, SUVN-G3031 (Histamine-3 receptor antagonist), SUVN-911 (Nicotinic acetylcholine alpha-4-beta-2 receptor antagonist), SUVN-D4010 (5-HT4 receptor partial agonist), SUVN-512 (5HT6 antagonists), CB2 agonist and M! modulators to treat the unmet medical needs of patients living with cognitive dysfunction associated with Alzheimer’s, schizophrenia, ADHD, depression and mood disorders and neuropathic pain would be presented by Suven scientists at SFN-2013.
Suven is committed to neuroscience research and development of new treatments for neurological disorders. Suven’s discovery research focuses on Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches.